Baidu
map

SCI REP:梗阻性肥厚型心肌病患者室间隔酒精消融术后并发症和长期结局如何?

2017-08-28 xing.T MedSci原创

总之,在ASA的围手术期死亡率和并发症是较为罕见的。ASA后长期生存率相比于NOHCM患者较为满意。40岁以下患者接受ASA治疗应更加谨慎,这些患者更容易在ASA围手术期耐受致命性室性心律失常。

室间隔酒精消融(ASA)术后并发症和长期生存率数据在中国梗阻性肥厚型心肌病(HOCM)患者中仍是缺乏的。近日,Scientific reports 杂志上发表了一篇研究文章,研究人员的目的是探讨HOCM患者接受ASA后长期生存率,并与非梗阻性肥厚型心肌病(NOHCM)患者进行比较。

该研究共招募了233例HOCM并且静息时峰值压力梯度≥50 mmHg的患者,这些患者在2000年至2012年期间连续就诊于中国阜外医院。另外,有297例无左室流出道梗阻者作为对照者。

研究人员发现ASA的围手术期死亡率较低(0.89%)。9例患者(4%)发生了围手术期致命性室性心律失常。酒精用量(RR为1.44,95%CI为1.03-2.03,P=0.034)和年龄小于40岁(RR为4.63,95%CI为1.07-20,P=0.040)是围手术期致死性室性心律失常的独立预测因子。ASA患者10年总生存率为94.6%,与NOHCM组患者的92.9%相似(P=0.930)。

总之,在ASA的围手术期死亡率和并发症是较为罕见的。ASA后长期生存率相比于NOHCM患者较为满意。40岁以下患者接受ASA治疗应更加谨慎,这些患者更容易在ASA围手术期耐受致命性室性心律失常。

原始出处:

Shuo-yan An,et al. Procedural complication and long term outcomes after alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: data from China.Scientific reports. 2017. https://www.nature.com/articles/s41598-017-10144-0

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1757843, encodeId=54eb1e578435c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Dec 28 01:38:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924274, encodeId=df1b19242e491, content=<a href='/topic/show?id=a1444624457' target=_blank style='color:#2F92EE;'>#室间隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46244, encryptionId=a1444624457, topicName=室间隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05202500204, createdName=minhuang75_72521584, createdTime=Thu Feb 22 08:38:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642235, encodeId=13e01642235a1, content=<a href='/topic/show?id=0edf6246874' target=_blank style='color:#2F92EE;'>#梗阻性肥厚型心肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62468, encryptionId=0edf6246874, topicName=梗阻性肥厚型心肌病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f04b22885869, createdName=dlwang_26703134, createdTime=Fri Mar 23 10:38:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385095, encodeId=59d71385095b1, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421678, encodeId=d2a614216e814, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560252, encodeId=ea331560252ce, content=<a href='/topic/show?id=a9fd65826da' target=_blank style='color:#2F92EE;'>#消融术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65826, encryptionId=a9fd65826da, topicName=消融术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4415117207, createdName=dingxiaobo, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566261, encodeId=d4bf1566261b8, content=<a href='/topic/show?id=a9fd65826da' target=_blank style='color:#2F92EE;'>#消融术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65826, encryptionId=a9fd65826da, topicName=消融术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4415117207, createdName=dingxiaobo, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622276, encodeId=ab9116222e668, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=)]
    2017-12-28 丁鹏鹏
  2. [GetPortalCommentsPageByObjectIdResponse(id=1757843, encodeId=54eb1e578435c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Dec 28 01:38:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924274, encodeId=df1b19242e491, content=<a href='/topic/show?id=a1444624457' target=_blank style='color:#2F92EE;'>#室间隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46244, encryptionId=a1444624457, topicName=室间隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05202500204, createdName=minhuang75_72521584, createdTime=Thu Feb 22 08:38:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642235, encodeId=13e01642235a1, content=<a href='/topic/show?id=0edf6246874' target=_blank style='color:#2F92EE;'>#梗阻性肥厚型心肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62468, encryptionId=0edf6246874, topicName=梗阻性肥厚型心肌病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f04b22885869, createdName=dlwang_26703134, createdTime=Fri Mar 23 10:38:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385095, encodeId=59d71385095b1, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421678, encodeId=d2a614216e814, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560252, encodeId=ea331560252ce, content=<a href='/topic/show?id=a9fd65826da' target=_blank style='color:#2F92EE;'>#消融术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65826, encryptionId=a9fd65826da, topicName=消融术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4415117207, createdName=dingxiaobo, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566261, encodeId=d4bf1566261b8, content=<a href='/topic/show?id=a9fd65826da' target=_blank style='color:#2F92EE;'>#消融术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65826, encryptionId=a9fd65826da, topicName=消融术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4415117207, createdName=dingxiaobo, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622276, encodeId=ab9116222e668, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1757843, encodeId=54eb1e578435c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Dec 28 01:38:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924274, encodeId=df1b19242e491, content=<a href='/topic/show?id=a1444624457' target=_blank style='color:#2F92EE;'>#室间隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46244, encryptionId=a1444624457, topicName=室间隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05202500204, createdName=minhuang75_72521584, createdTime=Thu Feb 22 08:38:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642235, encodeId=13e01642235a1, content=<a href='/topic/show?id=0edf6246874' target=_blank style='color:#2F92EE;'>#梗阻性肥厚型心肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62468, encryptionId=0edf6246874, topicName=梗阻性肥厚型心肌病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f04b22885869, createdName=dlwang_26703134, createdTime=Fri Mar 23 10:38:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385095, encodeId=59d71385095b1, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421678, encodeId=d2a614216e814, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560252, encodeId=ea331560252ce, content=<a href='/topic/show?id=a9fd65826da' target=_blank style='color:#2F92EE;'>#消融术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65826, encryptionId=a9fd65826da, topicName=消融术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4415117207, createdName=dingxiaobo, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566261, encodeId=d4bf1566261b8, content=<a href='/topic/show?id=a9fd65826da' target=_blank style='color:#2F92EE;'>#消融术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65826, encryptionId=a9fd65826da, topicName=消融术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4415117207, createdName=dingxiaobo, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622276, encodeId=ab9116222e668, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1757843, encodeId=54eb1e578435c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Dec 28 01:38:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924274, encodeId=df1b19242e491, content=<a href='/topic/show?id=a1444624457' target=_blank style='color:#2F92EE;'>#室间隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46244, encryptionId=a1444624457, topicName=室间隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05202500204, createdName=minhuang75_72521584, createdTime=Thu Feb 22 08:38:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642235, encodeId=13e01642235a1, content=<a href='/topic/show?id=0edf6246874' target=_blank style='color:#2F92EE;'>#梗阻性肥厚型心肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62468, encryptionId=0edf6246874, topicName=梗阻性肥厚型心肌病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f04b22885869, createdName=dlwang_26703134, createdTime=Fri Mar 23 10:38:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385095, encodeId=59d71385095b1, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421678, encodeId=d2a614216e814, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560252, encodeId=ea331560252ce, content=<a href='/topic/show?id=a9fd65826da' target=_blank style='color:#2F92EE;'>#消融术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65826, encryptionId=a9fd65826da, topicName=消融术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4415117207, createdName=dingxiaobo, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566261, encodeId=d4bf1566261b8, content=<a href='/topic/show?id=a9fd65826da' target=_blank style='color:#2F92EE;'>#消融术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65826, encryptionId=a9fd65826da, topicName=消融术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4415117207, createdName=dingxiaobo, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622276, encodeId=ab9116222e668, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1757843, encodeId=54eb1e578435c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Dec 28 01:38:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924274, encodeId=df1b19242e491, content=<a href='/topic/show?id=a1444624457' target=_blank style='color:#2F92EE;'>#室间隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46244, encryptionId=a1444624457, topicName=室间隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05202500204, createdName=minhuang75_72521584, createdTime=Thu Feb 22 08:38:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642235, encodeId=13e01642235a1, content=<a href='/topic/show?id=0edf6246874' target=_blank style='color:#2F92EE;'>#梗阻性肥厚型心肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62468, encryptionId=0edf6246874, topicName=梗阻性肥厚型心肌病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f04b22885869, createdName=dlwang_26703134, createdTime=Fri Mar 23 10:38:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385095, encodeId=59d71385095b1, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421678, encodeId=d2a614216e814, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560252, encodeId=ea331560252ce, content=<a href='/topic/show?id=a9fd65826da' target=_blank style='color:#2F92EE;'>#消融术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65826, encryptionId=a9fd65826da, topicName=消融术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4415117207, createdName=dingxiaobo, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566261, encodeId=d4bf1566261b8, content=<a href='/topic/show?id=a9fd65826da' target=_blank style='color:#2F92EE;'>#消融术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65826, encryptionId=a9fd65826da, topicName=消融术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4415117207, createdName=dingxiaobo, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622276, encodeId=ab9116222e668, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1757843, encodeId=54eb1e578435c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Dec 28 01:38:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924274, encodeId=df1b19242e491, content=<a href='/topic/show?id=a1444624457' target=_blank style='color:#2F92EE;'>#室间隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46244, encryptionId=a1444624457, topicName=室间隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05202500204, createdName=minhuang75_72521584, createdTime=Thu Feb 22 08:38:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642235, encodeId=13e01642235a1, content=<a href='/topic/show?id=0edf6246874' target=_blank style='color:#2F92EE;'>#梗阻性肥厚型心肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62468, encryptionId=0edf6246874, topicName=梗阻性肥厚型心肌病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f04b22885869, createdName=dlwang_26703134, createdTime=Fri Mar 23 10:38:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385095, encodeId=59d71385095b1, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421678, encodeId=d2a614216e814, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560252, encodeId=ea331560252ce, content=<a href='/topic/show?id=a9fd65826da' target=_blank style='color:#2F92EE;'>#消融术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65826, encryptionId=a9fd65826da, topicName=消融术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4415117207, createdName=dingxiaobo, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566261, encodeId=d4bf1566261b8, content=<a href='/topic/show?id=a9fd65826da' target=_blank style='color:#2F92EE;'>#消融术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65826, encryptionId=a9fd65826da, topicName=消融术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4415117207, createdName=dingxiaobo, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622276, encodeId=ab9116222e668, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1757843, encodeId=54eb1e578435c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Dec 28 01:38:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924274, encodeId=df1b19242e491, content=<a href='/topic/show?id=a1444624457' target=_blank style='color:#2F92EE;'>#室间隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46244, encryptionId=a1444624457, topicName=室间隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05202500204, createdName=minhuang75_72521584, createdTime=Thu Feb 22 08:38:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642235, encodeId=13e01642235a1, content=<a href='/topic/show?id=0edf6246874' target=_blank style='color:#2F92EE;'>#梗阻性肥厚型心肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62468, encryptionId=0edf6246874, topicName=梗阻性肥厚型心肌病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f04b22885869, createdName=dlwang_26703134, createdTime=Fri Mar 23 10:38:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385095, encodeId=59d71385095b1, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421678, encodeId=d2a614216e814, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560252, encodeId=ea331560252ce, content=<a href='/topic/show?id=a9fd65826da' target=_blank style='color:#2F92EE;'>#消融术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65826, encryptionId=a9fd65826da, topicName=消融术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4415117207, createdName=dingxiaobo, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566261, encodeId=d4bf1566261b8, content=<a href='/topic/show?id=a9fd65826da' target=_blank style='color:#2F92EE;'>#消融术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65826, encryptionId=a9fd65826da, topicName=消融术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4415117207, createdName=dingxiaobo, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622276, encodeId=ab9116222e668, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1757843, encodeId=54eb1e578435c, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Dec 28 01:38:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924274, encodeId=df1b19242e491, content=<a href='/topic/show?id=a1444624457' target=_blank style='color:#2F92EE;'>#室间隔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46244, encryptionId=a1444624457, topicName=室间隔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05202500204, createdName=minhuang75_72521584, createdTime=Thu Feb 22 08:38:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642235, encodeId=13e01642235a1, content=<a href='/topic/show?id=0edf6246874' target=_blank style='color:#2F92EE;'>#梗阻性肥厚型心肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62468, encryptionId=0edf6246874, topicName=梗阻性肥厚型心肌病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f04b22885869, createdName=dlwang_26703134, createdTime=Fri Mar 23 10:38:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385095, encodeId=59d71385095b1, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421678, encodeId=d2a614216e814, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560252, encodeId=ea331560252ce, content=<a href='/topic/show?id=a9fd65826da' target=_blank style='color:#2F92EE;'>#消融术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65826, encryptionId=a9fd65826da, topicName=消融术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4415117207, createdName=dingxiaobo, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566261, encodeId=d4bf1566261b8, content=<a href='/topic/show?id=a9fd65826da' target=_blank style='color:#2F92EE;'>#消融术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65826, encryptionId=a9fd65826da, topicName=消融术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c4415117207, createdName=dingxiaobo, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622276, encodeId=ab9116222e668, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Aug 30 09:38:00 CST 2017, time=2017-08-30, status=1, ipAttribution=)]

相关资讯

Stroke:卒中后隐匿患者的护理(AHA/ASA声明)

美国心脏协会(AHA)/ 美国卒中协会(ASA)新近的科学声明指出,将解决问题、压力管理类的技能训练和实践教育相结合助于改善卒中幸存者及其照顾者的生活质量。该声明还指出接受了 5~9 次的面对面或电话会议式的个体化干预措施的患者预后非常好。新证据为制订照看者护理计划方面的建议提供了理论基础,有助于改善对卒中幸存者及其家庭的护理。本述评及相关建议由 AHA 委员会心血管和卒中护理及卒中委员会组织

Thromb Haemostasis:12个月和30个月双联抗血小板治疗对死亡率和癌症有何影响?

这一分析表明PCI术后患者常规进行12个月DAPT后再额外接受18个月的治疗患者患癌症的风险稍有增加,但不能改善死亡率。这些数据并不支持在东亚人中进行DAPT超过1年。未来研究中分析癌症发生类型和评估潜在的癌症相关出血是必要的。

AHA发布脑静脉血栓形成新指南

  美国心脏学会(AHA)和美国卒中学会(ASA)2011年2月3日发布了首个关于脑静脉血栓形成的科学声明。声明中的建议有助于临床医师发现这种主要见于年轻卒中患者的罕见病因。   “脑静脉血栓形成的诊断和处理需要一个高水平的怀疑”,委员会主席Gustavo·Saposnik博士说。“指南就是要提高对这类疾病的察觉与识别。”   委员会包括一个来自美国、加拿大、墨西哥、葡萄牙和阿根廷的多学科专家

美国麻醉医师协会发布避免疼痛的五大“明智选择”

为响应美国内科学委员会基金会(ABIM)对疼痛干预混乱治疗方法的强烈呼吁,美国麻醉医师协会发布了疼痛医学领域前5种最值得商榷的检测和治疗方法。该文发表在2014年1月21的Medscape上。 2012年,美国内科学委员会基金会(ABIM)开展名为“明智选择”的活动,要求美国医学会列出一份5种最常用但缺乏证据支持的干预或检测方法的清单。目前为止,已列出此清单的协会有:美国皮肤科学研究院、美国家庭

Baidu
map
Baidu
map
Baidu
map